rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Brian Philippe Tinmouth

Director

Company insider

Files Form 4 as: Director, Scynexis; Chief Bus. & Strategy Officer, Pardes Biosciences.

Every Form 4 they filed

In numbers

Trades disclosed
20
Buys
1
Sells
0
Bought
$50K
Sold
$0
Companies
2
Companies where not an officer
1
First trade
13 Dec 2019
Last trade
26 Jun 2026
Last filed
30 Jun 2026

Companies traded

Where they are an officer
Pardes BiosciencesOfficer · last 14 Sep 20220 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
SCYX ScynexisDirector · Biotechnology · last 26 Jun 20261 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
26 Jun 2026filed 30 Jun 2026SCYX ScynexisBiotechnologySEC FORM 4 Code A—2,875 at $0.00filing
26 Jun 2026filed 30 Jun 2026SCYX Scynexisoption or derivative · BiotechnologySEC FORM 4 Code A—2,875 at $0.00filing
26 Jun 2026filed 30 Jun 2026SCYX Scynexisoption or derivative · BiotechnologySEC FORM 4 Code A—2,875 at $0.00filing
26 Jun 2026filed 30 Jun 2026SCYX ScynexisBiotechnologySEC FORM 4 Code A—2,875 at $0.00filing
26 Jun 2025filed 30 Jun 2025SCYX Scynexisoption or derivative · BiotechnologySEC FORM 4 Code A—23,000 at $0.00filing
26 Jun 2025filed 30 Jun 2025SCYX ScynexisBiotechnologySEC FORM 4 Code A—23,000 at $0.00filing
20 Jun 2024filed 21 Jun 2024SCYX Scynexisoption or derivative · BiotechnologySEC FORM 4 Code A—23,000 at $0.00filing
20 Jun 2024filed 21 Jun 2024SCYX ScynexisBiotechnologySEC FORM 4 Code A—23,000 at $0.00filing
15 Jun 2023filed 23 Jun 2023SCYX ScynexisBiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
15 Jun 2023filed 20 Jun 2023SCYX Scynexisoption or derivative · BiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
14 Sep 2022filed 16 Sep 2022Pardes Biosciencesoption or derivativeSEC FORM 4 Code A—125,000 at $0.00filing
17 Jun 2022filed 22 Jun 2022SCYX Scynexisoption or derivative · BiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
17 Jun 2022filed 22 Jun 2022SCYX ScynexisBiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
16 Jun 2021filed 21 Jun 2021SCYX Scynexisoption or derivative · BiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
21 Dec 2020filed 23 Dec 2020SCYX Scynexisoption or derivative · BiotechnologySEC FORM 4 Code A—4,000filing
21 Dec 2020filed 23 Dec 2020SCYX Scynexisoption or derivative · BiotechnologySEC FORM 4 Code A—4,000filing
21 Dec 2020filed 23 Dec 2020SCYX ScynexisBiotechnologySEC FORM 4 Bought$50K8,000 at $6.25filing
6 Jul 2020filed 31 Mar 2021SCYX Scynexisoption or derivative · BiotechnologySEC FORM 4 Code A—55,000 at $0.00filing
6 Jul 2020filed 8 Jul 2020SCYX Scynexisoption or derivative · BiotechnologySEC FORM 4 Code A—45,000 at $0.00filing
13 Dec 2019filed 17 Dec 2019SCYX Scynexisoption or derivative · BiotechnologySEC FORM 4 Code A—70,000 at $0.00filing

News

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)SCYX · manilatimes.net · 6 Oct 2026

0 headlines in the last 90 days name Brian Philippe Tinmouth; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.

Sectors

Health Care1

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.